Longeveron receives Japan patent for stem cell potency testing methods
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
January 29, 2026 9:15 AM ESTThe patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeverons growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeverons proprietary mesenchymal stem cell therapy, has delivered positive initial results across five clinical trials in three indications, including Hypoplastic Left Heart... More
